For two weeks, start a design, deck, or doc in the Claude app, and the work that follows in that conversation uses 50% less of your usage limits.
Give it a try with Claude Sonnet 5.5. It has a strong eye for design and builds slides that need minimal editing.
#Breaking: HHS announced a set of new initiatives aimed at speeding up clinical trials by incorporating more artificial intelligence and computational models and moving away from sharply delineated trial phases. https://t.co/hPg7dMOx2j
@nivek883@ealarkin7 I think most of the patients who choose Valius are more complicated and donโt have straightforward great success rates. They have many osteosarcoma patients and osteo is rarely curative after relapse. These patients deserve all that science can offer if they could die
Thank you @cdanicas and the @GuardConsortium team for inviting me to deliver a Keynote talk! Great meeting with so many thoughtful Spanish colleagues and friends!
What happened to the LAGE-1 TCR-T?
Angiosarcoma patient of ours has profoundly elevated LAGE-1 levels (99th percentile versus basically every cohort in our database.)
Lete-cel registrational trial (in sarcomas!) seemed to be positive 2 years ago, but then never filed after Adaptimmune sold assets to US World Meds?
@AnthropicAI announced they discovered a new enzyme system like CRISPR through Claude assistance.
They released a pre-print about the work alongside a lukewarm quote from Feng Zhang, while conveniently announcing their new wet lab that has been in the rumor mill over the last few days. Curious to see what the gene editing field thinks about the preprint after the hype dissipates a bit.
Wild if true, I am hopeful AI will accelerate scientific discoveries, so will keep fingers crossed!
https://t.co/25bPRdPl5F
#Claude #AI